Navigation Links
Urologists, Radiologists, Patients Benefit From New Clinical Prostate Visualization System
Date:9/30/2009

PEWAUKEE, Wis., Sept. 30 /PRNewswire/ -- The introduction of Invivo Corporation's DynaCAD for Prostate advanced clinical visualization and MR interventional system brings new hope to patients and new confidence to their care providers, a positive development this Prostate Cancer Awareness Month.

A five-year collaborative effort with Fox Chase Cancer Center, PA; Radboud University of Nijmegen, The Netherlands; University of Chicago, IL; and Desert Medical Imaging, CA resulted in an advanced solution that combines imaging and intervention options for patients with elevated or rising PSA levels and negative TRUS-guided biopsy results. DynaCAD for Prostate and DynaTRIM (Trans-Rectal Interventional MRI) allow Urologists, Oncologists and Radiologists to offer their patients an alternative to remaining in an uncertain state of diagnosis.

DynaCAD for Prostate provides physicians with customizable, advanced visualization tools for real-time analysis of MRI studies. Together with DynaTRIM, physicians can conduct targeted MRI interventions of suspicious areas within the prostate, reducing the number of cores acquired during biopsy. According to Dr. John Feller, Chief Medical Officer at Desert Medical Imaging, "DynaCAD for Prostate provides increased operational efficiency, enabling radiologists to rapidly interpret 3,000 images that constitute a dynamic contrast-enhanced prostate MRI."

Many patients who present with an elevated PSA undergo multiple TRUS-guided biopsies with negative results. While the TRUS targets the whole prostate, DynaTRIM focuses only on suspicious areas. "The results of our clinical evaluation revealed that DynaCAD for Prostate and DynaTRIM offer a better alternative for appropriate patients, and those results have been duplicated in the daily practices of physicians," said Susan Reisker, Product Marketing Manager at Invivo Corporation. "We're seeing patients traveling to centers where this advanced solution is now available and finally receiving firm diagnosis after experiencing multiple negative TRUS-guided biopsies." Dr. Inge von Oort, Oncological Urologist at the University of Nijmegen Medical Center, agrees. "Especially for patients who've had several negative biopsies, a maximum of only 4 MR-guided biopsy cores is required with a detection rate of 59%." Reisker adds, "Compared to published cancer yield rates of up to 15% with third TRUS-guided biopsies, the increased detection rate gives greater confidence to physicians and patients."

In addition to improved diagnostic abilities, physicians benefit from the scalability and cost-effective nature of DynaCAD for Prostate. Whether they require stand-alone workstations or broad enterprise systems, Invivo provides cost-effective upgrades to accommodate physicians' increased volume. "We developed this solution with patients' well-being and physicians' practices in mind," said Reisker. "DynaCAD for Prostate's flexible interface, alongside DynaTRIM, can easily become an important part of any practice interested in prostate imaging and intervention."

Invivo Corporation has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices. Invivo successfully develops, manufactures and markets high-value-added medical instruments that enhance MR image quality, improving physicians' diagnostic confidence and patients' health care experience.

SOURCE Invivo Corporation


'/>"/>
SOURCE Invivo Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
3. Capecitabine Added to Standard Treatment Given Before Surgery Helps to Eradicate Tumours in Patients With Early Breast Cancer
4. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
5. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
6. Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
7. Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
10. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
11. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):